Pfizer's 2023 Sales: A Deep Dive into Product Categories

In 2023, Pfizer's sales landscape showcases a diverse portfolio, with Primary Care leading the charge, contributing to nearly 40% of the total sales. This category's dominance underscores Pfizer's strategic focus on broad healthcare solutions. Notably, COMIRNATY®, the renowned COVID-19 vaccine, follows closely, accounting for approximately 15% of sales, reflecting its continued global demand.

ELIQUIS® and the PREVNAR® Family also make significant contributions, each representing around 9% of the total sales. These figures highlight Pfizer's robust presence in both cardiovascular and vaccine markets. Meanwhile, IBRANCE® and the VYNDAQEL® Family further diversify the company's revenue streams, emphasizing its commitment to oncology and rare diseases.

Interestingly, categories like Anti-Infectives and Business Innovation show minimal sales, suggesting potential areas for growth or strategic reevaluation. This data offers a comprehensive view of Pfizer's market dynamics in 2023, providing valuable insights for stakeholders and investors.